TY -的T1 -急性hypoxaemic呼吸道失败者e in immunocompromised patients: abandon bronchoscopy or make it better? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01950-2019 VL - 54 IS - 6 SP - 1901950 AU - Zinter, Matt S. AU - Cheng, Guang-Shing Y1 - 2019/12/01 UR - //www.qdcxjkg.com/content/54/6/1901950.abstract N2 - Acute hypoxemic respiratory failure (AHRF) in immunocompromised patients is a challenging clinical problem associated with mortality rates of 40–60% in children and adults [1, 2]. Thus, we read with great interest the results of a pre-planned secondary analysis of a large multicentre observational cohort of 1611 immunocompromised adults with AHRF, as reported by Bauer et al. [3]. The authors described the diagnostic yield and outcomes of fibreoptic bronchoscopy (FOB) in this group of vulnerable patients with the a priori hypothesis that “bronchoscopy, with limited complications, would reduce the number of unidentified causes of respiratory failure and be associated with reduced hospital mortality.” After a rigorous analysis of a highly annotated dataset, the authors conclude that “bronchoscopy was associated with improved diagnosis and changes in management but also increased hospital mortality.”A discussion of the strengths and limitations of recent data associating bronchoscopy with mortality in immunocompromised adults with acute hypoxaemic respiratory failure http://bit.ly/31mMpGL ER -